M. Campelo

Most-cited papers

1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.

   E. Felip, B. Cho, V. Gutiérrez, A. Alip +46 more

   2024Annals of Oncology104 citations Open access

   Semantic Scholar

   Save

2. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

   M. Thomas, S. Ponce-Aix, A. Navarro, J. Riera-Knorrenschild +33 more

   2018Annals of Oncology76 citations Open access

   Semantic Scholar

   Save

3. Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer

   Adrianna Janik, M. Torrente, Luca Costabello, V. Calvo +13 more

   2023JCO Clinical Cancer Informatics25 citations Open access

   Semantic Scholar

   Save

4. Machine Learning-Assisted Recurrence Prediction for Early-Stage Non-Small-Cell Lung Cancer Patients

   Adrianna Janik, M. Torrente, Luca Costabello, V. Calvo +13 more

   2022arXiv.org7 citations Open access

   Semantic Scholar

   Save

5. MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC

   T. Mok, B. Solomon, M. Campelo, Y.-L. Wu +8 more

   2024Journal of Thoracic Oncology6 citations

   Semantic Scholar

   Save

6. Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

   E. Felip, G. Metro, R. Soo, Jürgen Wolf +19 more

   2024European Journal of Cancer2 citations

   Semantic Scholar

   Save

7. Machine Learning Survival Models for Relapse Prediction in a Early Stage Lung Cancer Patient

   Mohan Timilsina, Samuele Buosi, Adrianna Janik, Pasquale Minervini +11 more

   2023IEEE International Joint Conference on Neural Network2 citations Open access

   Semantic Scholar

   Save

8. Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations

   A. Bearz, J. Martini, J. Jassem, Sang-We Kim +11 more

   2021Clinical research2 citations

   Semantic Scholar

   Save

9. P3.229: Patterns of Progression and Efficacy of Subsequent Therapy in Patients With Advanced ALK+ NSCLC in the Phase 3 CROWN Study

   T. Bauer, A. T. Shaw, T. Mok, M. Campelo +10 more

   2026Journal of Thoracic Oncology0 citations

   Semantic Scholar

   Save

10. Osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

    J. Goldman, J. Riess, Byoung Chul Cho, S. Goldberg +21 more

    2026Clinical Lung Cancer0 citations Open access

    Semantic Scholar

    Save

11. Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial

    Myung-Ju Ahn, A. Delmonte, Sharmistha Ghosh, M. Hochmair +16 more

    2025Future Oncology0 citations Open access

    Semantic Scholar

    Save

12. PP237 Overall and Asian subpopulation analysis of real-world treatment patterns and effectiveness of subsequent treatments following first-line brigatinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer from ALTA-1L

    A. Delmonte, M. Ahn, S. Ghosh, M. Hochmair +17 more

    2025ESMO Open0 citations Open access

    Semantic Scholar

    Save

13. P1.09-04 Comprehensive Genomic Profiling in a Brazilian Cohort of Lung Cancer Patients: Real-World Impact

    T. Padua, M. Monteiro, M. Silvino, L. Carvalho +9 more

    2019Journal of Thoracic Oncology0 citations Open access

    Semantic Scholar

    Save